Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.

Trial Profile

Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top